Pfizer Inc
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer Total Biopharma Royalty Revenues by Quarter
Total Biopharma Royalty Revenues (cross-portfolio summary) — U.S. revenues ($M) ($M)
Pfizer Total Biopharma Royalty Revenues: $471M in Q2 2026, up 11.3% from a year earlier.
Where the Q2 2026 figure comes from
“|| Total Royalty revenues included above | $ | 474 | $ | 426 | 11% | 11% | $ | 471 | $ | 423 | 11% | $ | 3 | $ | 3 | 20% | 15%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up total Biopharma Royalty Revenues
Cite this data
StockData. (2026). Pfizer Total Biopharma Royalty Revenues ($M), quarterly Q2 2023–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/royalty-rev-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.
See a number that looks wrong?